Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACAM-CDIFF
- Development stage
- Phase 2
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**ACAM-CDIFF** is an investigational toxoid vaccine developed by Sanofi Pasteur to prevent primary Clostridium difficile infection (CDI). It contains inactivated forms of **toxin A (TcdA)** and **toxin B (TcdB)** from C. difficile, designed to elicit neutralizing antibodies against these key virulence factors responsible for CDI pathogenesis. Administered via intramuscular injection, the vaccine aims to provide prophylactic immunity in at-risk populations such as the elderly or those exposed to CDI risk factors. Phase II trials demonstrated immunogenicity with serum and mucosal antibody responses but development appears to have stalled without advancement to phase III approval.[1][2][5][7][8][9]
- Brand names
- Cdiffense
- Other names
- ACAM-CDIFF™Clostridium Difficile Toxoid Vaccine
02
Targets
TcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on ACAM-CDIFF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACAM-CDIFF.